Despite the metabolite signature determined for the early stage of DN being characterized by a diagnostic performance of 81%, these metabolites as potential biomarkers might be useful in the evaluation of treatment of the disease, especially at early stages that may reduce the risk of kidney failure development than existing creatinine/albumin-based tests. This evidence concerns the gene ALB and liver dysplastic nodule.